Immutep (Prima Biomed) | PRR | Pharmaceuticals & biotechnology
Performance | Valuation | Growth | Summary | Balance Sheet | Income Statement | Cash Flow
A$ in Million except per share figures. Fiscal year ends in June. Figures are consolidated and restated.
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | ||
Revenue |  | 0.48 | 1 | 4 | 4 | 3 | 2 | 2 | 4 |
Cost of revenue | | -5 | -10 | -15 | -14 | -12 | -9 | -7 | -8 |
Gross Profit | | -5 | -8 | -11 | -10 | -9 | -7 | -5 | -3 |
Depreciation | | -0.05 | -0.06 | -0.38 | -0.25 | -0.45 | -1 | -2 | -2 |
Provision | | 0 | -0.57 | -1 | 0 | 0 | 0 | -0.56 | 0 |
Other op inc/exp... | | 0 | 0 | -1 | -0.03 | 0 | -0.01 | -49 | -0.75 |
Operating income | | -11 | -15 | -20 | -15 | -13 | -14 | -63 | -10 |
Interest expense | | -7 | -6 | 0 | 0 | 0 | -18 | -0.01 | 0 |
Other income/exp... | | 0.07 | 0 | 0 | 0 | 0 | 0 | 0.26 | -0.27 |
Profit before tax | | -18 | -21 | -20 | -15 | -13 | -32 | -63 | -10 |
Income tax & other ta... | | 0 | 0 | 0 | 0.09 | 0.01 | -0.14 | -1 | -0.74 |
Net income from c... | | -18 | -21 | -20 | -15 | -13 | -32 | -62 | -10 |
Extraordinary & disc... | | 0 | 0 | 0 | 0 | 0 | -0.06 | 0.61 | 0 |
Minority Interest | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net Income | | -18 | -21 | -20 | -15 | -13 | -32 | -61 | -10 |
NI - Preferred Di... | | -18 | -21 | -20 | -15 | -13 | -32 | -61 | -10 |
Basic shares | | 500 | 564 | 1,038 | 1,075 | 1,440 | 1,591 | 2,236 | 2,072 |
Diluted Shares | | 500 | 564 | 1,038 | 1,075 | 1,440 | 1,591 | 2,236 | 2,072 |
EPS Basic | | -0.036 | -0.037 | -0.019 | -0.014 | -0.009 | -0.020 | -0.027 | -0.005 |
EPS Diluted | | -0.036 | -0.037 | -0.019 | -0.014 | -0.009 | -0.020 | -0.027 | -0.005 |